FAQ on Quantum BioPharma Ltd.'s $600 Private Placement of Class A Multiple Voting Shares

What is Quantum BioPharma Ltd. announcing?

Quantum BioPharma Ltd. is announcing a non-brokered private placement of Class A Multiple Voting Shares (MVS) at $50 per share for gross proceeds of up to $600.

Who is expected to subscribe to the private placement?

The offering is expected to be fully subscribed by existing MVS holders, including entities linked to CEO Zeeshan Saeed and director Anthony Durkacz.

What will the proceeds from the private placement be used for?

The proceeds will support general working capital.

Are there any restrictions on the securities issued?

Yes, all issued securities will carry a four-month-plus-one-day hold under Canadian securities laws.

What is Quantum BioPharma Ltd.’s focus?

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.

What is Lucid-MS?

Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

What is UNBUZZD(TM)?

UNBUZZD(TM) is a product invented by Quantum BioPharma, with an OTC version spun out to Celly Nutrition Corp., where Quantum BioPharma retains ownership of 25.71% and receives royalty payments from sales.

Where can investors find the latest news and updates relating to QNTM?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What is BioMedWire?

BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, part of the Dynamic Brand Portfolio @ IBN.